<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5922">
  <stage>Registered</stage>
  <submitdate>31/12/2015</submitdate>
  <approvaldate>31/12/2015</approvaldate>
  <nctid>NCT02654132</nctid>
  <trial_identification>
    <studytitle>An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)</studytitle>
    <scientifictitle>An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-003282-19</secondaryid>
    <secondaryid>CA204-125</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Elotuzumab
Treatment: drugs - Pomalidomide
Treatment: drugs - Dexamethasone

Experimental: Elotuzumab Arm - Biological:Elotuzumab (BMS-901608; HuLuc63)
Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)
Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)
Drug: Pomalidomide
Capsules,Oral,4 mg,once daily, on Days 1-21
Other Name: Pomalyst
Drug: Dexamethasone
Subjects = 75 years old:
Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&amp;2) Day 1(Cycle 3 and Beyond)
Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&amp;2) Day 1(Cycle 3 and Beyond)
Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)
Subjects &gt; 75 years old:
Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&amp;2) Day 1(Cycle 3 and Beyond)
Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&amp;2) Day 1(Cycle 3 and Beyond)
Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)
Other Names:
Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak

Active Comparator: Control Arm - Drug: Pomalidomide
 Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst
Drug: Dexamethasone
Subjects = 75 years old:
 Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22
Subjects &gt; 75 years old:
 Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,
Other Names:
Decadron
Dexamethasone Intensol
Dexpak
Taperpak


Treatment: drugs: Elotuzumab


Treatment: drugs: Pomalidomide


Treatment: drugs: Dexamethasone


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS) - PFS will be defined as the time, in months, from randomization to the date of the first documented tumor progression or death due to any cause</outcome>
      <timepoint>Approximately 14 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR)</outcome>
      <timepoint>Approximately 14 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Approximately 32 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        

          -  = 2 prior lines of therapy which must have included at least 2 consecutive cycles of
             lenalidomide and a proteosome inhibitor alone or in combination

          -  Documented refractory or relapsed and refractory multiple myeloma

          -  Refractory to proteosome inhibitor and lenalidomide, and to last treatment

          -  Relapsed and refractory patients must have achieved at least a partial response to
             previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed
             within 6 months, and were refractory to their last treatment

          -  Measurable disease at screening

          -  Eastern Cooperative Oncology Group (ECOG) performance status = 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active plasma cell leukemia

          -  Prior treatment with pomalidomide

          -  Unable to tolerate thromboembolic prophylaxis while on the study

          -  Prior autologous stem cell transplant within 12 weeks

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>16/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>121</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>22/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Local Institution - South Brisbane</hospital>
    <postcode>4101 - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Pierre Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Iwate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastrict</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Celgene</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>AbbVie</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose
      dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma
      compared to pomalidomide and low-dose dexamethasone by itself.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02654132</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>